卵巢癌是一种很难早期发现的癌症，一旦诊断出来，往往为时已晚。考虑到卵巢癌几乎对现有的所有免疫疗法都没有反应，而该研究发现，阻断IL-4能够改变卵巢肿瘤微环境，使这种难治性肿瘤变得更容易治疗，这对卵巢癌研究来说是一个重大突破。

The therapeutic candidate is under development for the treatment of ovarian cancer. It comprises of induced pluripotent stem (iPS) cell derived natural killer (iNK) cell.

The theory is solid, but creating such a bespoke vaccine quickly enough to be of use is a different matter. “Not many years ...

A phase 1 trial evaluating FSHR-targeting CAR T cells for patients with ovarian cancer has dosed the first patient in its ...

Onvapegleukin alfa is under clinical development by Ascendis Pharma and currently in Phase II for Ovarian Cancer.

The immune system fights cancer by allowing cells to communicate and work together. This study investigated which cell types in ovarian cancer tumors interact with one another, especially after ...

Experts say ovarian cancer causes more deaths than all other female reproduction system cancers and is difficult to diagnose ...